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I NTRO D U C TIO N
Parathyroid adenoma is a major cause of primary hyperparathyroidism, with an incidence of 80%-85%. (1) Currently, t he primar y me t ho d of t reat ment is parathyroidectomy. (2, 3) This method of treatment, however, may not be possible when there is a high surgical risk or contraindication for surgery, or when the patient is reticent to undergo surgical procedures. The latter being a concern raised mainly by women due to the possibility of a resulting postoperative scar. Hence, in most cases, parathyroidectomy is only performed on selected patients.
With the swift development of minimally invasive and highly specific techniques, percutaneous sonography-guided radiofrequency ablation (RFA) therapy has been steadily progressing and yielding good clinical results. (4) (5) (6) (7) While RFA has been used as a reasonably effective method to treat some primary and secondary tumours of the thyroid, (4) lung (5, 6) and liver, (7) the procedure is not limited to these organs. This report describes our experience with RFA in the treatment of parathyroid adenoma, and aims to assess the safety, effectiveness and durability of this procedure for the treatment of parathyroid adenoma. Tc-sestamibi scintigraphy performed after ablation revealed no abnormal uptake. Fig. 2 shows the difference in uptake pre-and post procedure. Four days after the procedure, the patient presented with hypocalcaemia (1.84 mmol/L), which was resolved (2.68 mmol/L) within two weeks with the use of calcium replacement therapy. Two months after the procedure, the patient's serum levels of PTH, calcium and phosphate had normalised, and there was a reduction in his gastrointestinal and bone disease symptoms.
Case 2
A 54-year-old man with a ten-year history of type 2 diabetes mellitus and a two-week history of general fatigue and bone pain was admitted to our hospital. He had a markedly elevated PTH level (> 1,900 ng/L) and hypercalcaemia (8) (9) (10) Evidence in the form of higher survival rates, better local control, lower recurrence rates and complete radiological tumour response supports RFA as a procedure superior to ethanol ablation. (11, 12) Furthermore, ethanol ablation requires periodic re-injections in order to achieve a complete cure.
This increases the risk of complications such as haemorrhage, transient alcohol intoxication, local pain and tumour cell seeding. Laser thermal ablation is not commonly used due to the high cost of the sophisticated equipment. As such, percutaneous sonography-guided RFA therapy was selected in the two cases described.
In our study, one of the two patients presented with transient hoarseness after RFA, but this was spontaneously resolved two days after the procedure. Beyond that, no other complications were observed and the whole RFA Tc-sestamibi scintigraphy is the method of choice for localisation of parathyroid adenomas due to its high diagnostic sensitivity (> 90%). (14) CT and MR imaging are helpful in the diagnosis and further delineation of the location of the adenomatous tissue. (15) The two patients in our study were subject to a mixture of the aforementioned localisation techniques so as to improve the accuracy of diagnosis and localisation of the parathyroid adenoma.
As parathyroid adenoma is a rare disease, data from large retrospective studies and randomised trials for the verification of therapeutic options are limited. Therefore, physicians may have to make management decisions based on evidence from case reports while further evaluating the therapeutic efficacy of RFA through long-term accumulation of experience.
In conclusion, the use of ultrasonography-guided percutaneous RFA in the management of parathyroid adenoma is safe and yields a high degree of recovery from hypercalcaemia. As RFA is an effective therapeutic option for the management of parathyroid adenoma, its clinical application should be considered and made more widespread. 
